RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Raw

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Collaboration revenue - related party----8413200
Research and Development Expense (Excluding Acquired in Process Cost)------2857101160238
General and administrative7881111121326359561
Total operating expenses11141631414611183136255299
Loss from operations-7-11-13-27-33-42-110-80-134-254-299
Interest and other income--------51932
Interest and other expense----------3
Other income, net---0110041729
Net loss-8-11-13-27-33-42-111-79-130-238-270
Series A Preferred Stock-----------204.82
Series B Preferred Stock-----------204.82
Earnings Per Share, Basic--------6.66-4.05-5.31-
Series A Preferred Stock-----------204.82
Series B Preferred Stock-----------204.82
Earnings Per Share, Diluted--------6.66-4.05-5.31-
Net loss-8-11-13-27-33-42-111-79-130-238-270
Change in unrealized (loss) gain on investments---------1-0
Total other comprehensive (loss) income---------01-0
Total comprehensive loss-----33-42-111-80-130-237-270